

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
29 December 2022 (29.12.2022)



(10) International Publication Number
WO 2022/269269 A1

(51) International Patent Classification:
C12N 15/86 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:
PCT/GB2022/051611

(22) International Filing Date:
23 June 2022 (23.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2108997.4 23 June 2021 (23.06.2021) GB
2111317.0 05 August 2021 (05.08.2021) GB

(71) Applicants: **SYNPROMICS LIMITED** [GB/GB]; Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **ASKLEPIOS BIOPHARMACEUTICAL, INC.** [US/US]; 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina, 27709 (US).

(72) Inventors: **YANEZ-CUNA, Jorge Omar**; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **IGLESIAS, Juan Manuel**; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **COOPER, Sinclair**; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB). **ROBERTS, Michael L.**; c/o Synpromics, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB).

EVRIPIOTI, Antonia; c/o Synpromics Ltd, Roslin Innovation Centre, Easter Bush Campus, Midlothian EH25 9RG (GB).

(74) Agent: **HGF LIMITED (GLASGOW)**; 1 City Walk, Leeds West Yorkshire LS11 9DX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: REGULATORY NUCLEIC ACID SEQUENCES




Fig. 12

(57) Abstract: The present invention relates to regulatory nucleic acid sequences, in particular muscle-specific promoters, elements thereof, and other such nucleic acid sequences, that are capable of enhancing muscle-specific expression of genes. The invention also relates to expression constructs, vectors and cells comprising such muscle-specific regulatory nucleic acid sequences, and to methods of their use. The regulatory nucleic acid sequences are of particular utility for gene therapy applications, but also find utility in other areas such as bioprocessing and biotechnology.

WO 2022/269269 A1

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*